English: Diolch, Dirprwy Lywydd. Our NHS is in dire peril. We are now a week away from the election. The election that's meant to get Brexit done, according to Boris Johnson. Meanwhile, Donald Trump is visiting the UK to assure us that he has no plans to gain market access to our NHS. Both these viewpoints are lies. The Conservatives' Brexit plans will not get Brexit done. Passing the withdrawal agreement will only be the end of the beginning, while the future relationship negotiations are yet to begin. And Donald Trump's assurances are about as reliable as a Tory manifesto commitment for Wales, unfortunately. Trump said yesterday that he wouldn't want the NHS to form part of any deal, and that he also had no idea who started this vicious rumour in the first place. Well, I can help him with that because it was, of course, Donald Trump himself who did just that. During a visit to the UK on 4 June, he was asked whether the NHS should be on the table, and his answer was: 'When you're dealing in trade everything's on the table, so NHS or anything else or a lot more than that but everything will be on the table, absolutely.' So, that's clear, then. Two days earlier, the American ambassador, Woody Johnson, had told Andrew Marr the same thing. There is also clear evidence that gaining partial access to the NHS forms a big part of the US's trade objectives, which are to be found in an official US department for trade document entitled 'United States-United Kingdom Negotiations'. Further proof was contained in the documents released last week by the Labour Party, which show exploratory talks were already ongoing and that drug patents and pricing, health insurance and medical devices were discussed. And only yesterday, Dominic Raab confessed on Sky News that US companies could indeed increase drug prices for the NHS through provisions likely to be enacted in a future trade deal. Now, I think it would be useful to give some detail about what exactly the US is after here, and how it could affect patients here. We're not talking about privatising the whole of the health service. Private companies would have no interest in running accident and emergency departments, for example, because, to put it bluntly, there are no easy profits to be made there. What they want is to cherry-pick the most lucrative parts of the market, in order to divert money from front-line NHS services to the pockets of US big pharma. The simplest way of doing this is through changing rules around patents and drug pricing, which is exactly why these two factors form the main part of US negotiating demands. Now, if the US were successful in gaining full market access for US drugs, they would greatly limit the National Institute for Health and Care Excellence's ability to decide which medicines patients can receive. In the US, drug prices are inflated to, frankly, obscene levels, because the licensing is lengthy and under control of powerful lobbyists, which means only a few companies have the expertise to navigate the process.
Welsh: Diolch, Ddirprwy Lywydd. Mae ein GIG mewn perygl enbyd. Wythnos sydd i fynd cyn yr etholiad erbyn hyn. Yr etholiad sydd i fod i gael Brexit wedi'i wneud, yn ôl Boris Johnson. Yn y cyfamser, mae Donald Trump yn ymweld â'r DU i roi sicrwydd i ni nad oes ganddo unrhyw gynlluniau i gael mynediad i'r farchnad am ein GIG. Mae'r ddau safbwynt yn gelwydd. Ni fydd cynlluniau Brexit y Ceidwadwyr yn sicrhau bod Brexit yn cael ei wneud. Dim ond diwedd y dechrau fydd pasio'r cytundeb ymadael, ac mae'r negodiadau ar y berthynas yn y dyfodol eto i ddechrau. Ac mae sicrwydd Donald Trump mor ddibynadwy ag ymrwymiad maniffesto Torïaidd i Gymru, yn anffodus. Dywedodd Trump ddoe na fyddai'n dymuno i'r GIG fod yn rhan o unrhyw gytundeb, ac nad oedd ganddo syniad chwaith pwy ddechreuodd y si faleisus hon yn y lle cyntaf. Wel, gallaf ei helpu gyda hynny oherwydd mai Donald Trump ei hun wrth gwrs a wnaeth yn union hynny. Yn ystod ymweliad â'r DU ar 4 Mehefin, gofynnwyd iddo a ddylai'r GIG fod ar y bwrdd, a'i ateb oedd: Pan fyddwch chi'n ymwneud â masnach mae popeth ar y bwrdd, felly'r GIG neu unrhyw beth arall neu lawer mwy na hynny ond bydd popeth ar y bwrdd, yn bendant. Felly, mae hynny'n glir. Ddeuddydd yn gynharach, roedd y llysgennad Americanaidd, Woody Johnson, wedi dweud yr un peth wrth Andrew Marr. Mae tystiolaeth glir hefyd fod cael mynediad rhannol i'r GIG yn rhan fawr o amcanion masnach yr Unol Daleithiau, sydd i'w canfod mewn dogfen swyddogol gan adran fasnach yr UDA o dan y pennawd 'United States-United Kingdom Negotiations'. Cafwyd rhagor o dystiolaeth yn y dogfennau a ryddhawyd yr wythnos diwethaf gan y Blaid Lafur, sy'n dangos bod trafodaethau archwiliadol eisoes yn mynd rhagddynt a bod patentau a phrisiau cyffuriau, yswiriant iechyd a dyfeisiau meddygol wedi'u trafod. A ddoe ddiwethaf, cyfaddefodd Dominic Raab ar Sky News y gallai cwmnïau o'r UDA godi prisiau cyffuriau ar gyfer y GIG yn wir drwy ddarpariaethau sy'n debygol o gael eu gweithredu mewn cytundeb masnach yn y dyfodol. Nawr, rwy'n credu y byddai'n ddefnyddiol rhoi rhywfaint o fanylion ynglŷn â beth yn union y mae'r UDA ei eisiau yma, a sut y gallai effeithio ar gleifion yma. Nid ydym yn sôn am breifateiddio'r gwasanaeth iechyd cyfan. Ni fyddai gan gwmnïau preifat unrhyw ddiddordeb mewn rhedeg adrannau damweiniau ac achosion brys, er enghraifft, oherwydd, a siarad yn blwmp ac yn blaen, nid oes elw hawdd i'w wneud yno. Yr hyn y maent ei eisiau yw dewis a dethol y rhannau mwyaf proffidiol o'r farchnad, er mwyn dargyfeirio arian o wasanaethau rheng flaen y GIG i bocedi cwmnïau fferyllol mawr yr UDA. Y ffordd symlaf o wneud hyn yw drwy newid rheolau'n ymwneud â phatentau a phrisio cyffuriau, a dyna'n union pam mai'r ddau ffactor hwn sy'n ffurfio'r brif ran o ofynion negodi'r UDA. Nawr, pe bai'r UDA yn llwyddo i gael mynediad llawn i'r farchnad i gyffuriau'r Unol Daleithiau, byddent yn cyfyngu'n fawr ar allu'r Sefydliad Cenedlaethol dros Ragoriaeth mewn Iechyd a Gofal i benderfynu pa feddyginiaethau y gall cleifion eu cael. Yn yr Unol Daleithiau, mae prisiau cyffuriau wedi'u chwyddo i lefelau sy'n anweddus a dweud y gwir, oherwydd bod y drefn drwyddedu'n hirfaith ac o dan reolaeth lobïwyr pwerus, sy'n golygu mai ychydig gwmnïau'n unig sy'n meddu ar yr arbenigedd i lywio drwy'r broses.